Pharmacy Daily | Aussie Mexican HIV solution

A NEWLY created Australian pharmaceutical company aims to tackle the rising problem of HIV in Mexico and in the USA. John Majewski, who’s the retired founder and CEO of Narhex Life Sciences Limited, has negotiated an “exclusive technology license” from the company covering the territories of Mexico and the USA. The aim is to register Australia’s first new generation small molecule boosted protease inhibitor treatment for people living with HIV in these regions. A new corporate entity called Four Guardians Life Sciences has been formed, targeting the market which up to now has received older generation antiviral treatments which are no longer favoured in more lucrative western markets. Majewski said the approach is a “possible game changer” for second world countries like Mexico who need first world treatments but can’t afford western pricing. Narhex Life Sciences developed the product until Majewski’s retirement in 2005, and he’s taken on the new license because of significant support from his Mexican contract researcher and the Mexican ministry of Health - meaning phase 3 trials will be much cheaper and the product can be brought to market faster.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 23 Jul 12
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Jul 12